Can MRI reveal if enzyme therapy protects hearts in fabry disease?
NCT ID NCT02956954
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study followed 26 people with Anderson-Fabry disease, some taking the enzyme replacement drug Replagal® and some not, to see how their hearts changed over two years. Researchers used special MRI scans to measure heart tissue relaxation time, which may indicate early damage. The goal was to find a better way to monitor whether treatment is protecting the heart.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Agalsidase alpha (Replagal®)
- What this could lead to
- If successful, this could show that Replagal® improves heart structure and function in Fabry disease, offering a way to monitor treatment effectiveness with MRI.
- What could go wrong
- This is a small, observational study with only 26 patients, so results may not apply to everyone. It does not test a new treatment, only tracks existing therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANDERSON FABRY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rouen University Hospital
Rouen, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.